C07C 307/00
Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate
Official title: Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
C07C307/00 (Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate) appears on 394 US grants and 383 published applications in this corpus.
Search patents in C07C- Granted patents
- 394
- Published applications
- 383
- Assignees
- 274
- Inventors
- 1,318
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 3 | 0 |
| 1978 | 9 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 1 | 0 |
| 1993 | 8 | 0 |
| 1994 | 9 | 0 |
| 1995 | 2 | 0 |
| 1996 | 11 | 0 |
| 1997 | 8 | 0 |
| 1998 | 9 | 0 |
| 1999 | 8 | 0 |
| 2000 | 9 | 0 |
| 2001 | 17 | 2 |
| 2002 | 19 | 17 |
| 2003 | 14 | 16 |
| 2004 | 8 | 25 |
| 2005 | 9 | 17 |
| 2006 | 10 | 13 |
| 2007 | 18 | 15 |
| 2008 | 10 | 12 |
| 2009 | 10 | 16 |
| 2010 | 7 | 25 |
| 2011 | 5 | 12 |
| 2012 | 12 | 19 |
| 2013 | 19 | 16 |
| 2014 | 14 | 21 |
| 2015 | 20 | 10 |
| 2016 | 10 | 14 |
| 2017 | 11 | 17 |
| 2018 | 11 | 12 |
| 2019 | 11 | 12 |
| 2020 | 11 | 12 |
| 2021 | 11 | 15 |
| 2022 | 8 | 6 |
| 2023 | 5 | 18 |
| 2024 | 10 | 18 |
| 2025 | 9 | 15 |
| 2026 | 3 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Calpain-2 inhibitor compounds and methods of treatment21 Apr 2026US 12,606,520 B2Western University of Health Sciences
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives21 Apr 2026US 12,606,522 B2OrsoBio, Inc.
- FABP4/5 inhibitors, methods of use and methods of making10 Mar 2026US 12,570,603 B2Celloram Inc.
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- Modulators of liver receptor homologue 1 (LRH-1) and uses16 Sep 2025US 12,415,770 B2Emory University Office of Technology Transfer
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives16 Jul 2026US 2026/0200844 A1OrsoBio, Inc.
- Compounds and compositions for treating conditions associated with nlrp activity16 Jul 2026US 2026/0200880 A1Novartis AG
- Modulators of liver receptor homologue 1 (lrh-1) and uses25 Jun 2026US 2026/0176228 A1Emory University
- Fabp4/5 inhibitors, methods of use and methods of making14 May 2026US 2026/0132106 A1Celloram Inc.
- Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof2 Apr 2026US 2026/0092037 A1Praxis Precision Medicines, Inc.
Most cited
By later US patents
- Sulfonamide inhibitors of aspartyl protease147US 5,585,397 AVertex Pharmaceuticals Incorporated · 1996
- Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method125US 5,760,246 A1998
- Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs103US 5,366,997 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1994
- IL-8 receptor antagonists92US 5,886,044 ASmithKline Beecham Corporation · 1999
- Compounds and compositions for intracellular delivery of therapeutic agents88US 10,857,105 B2MordernaTX, Inc. · 2020